Publication | Closed Access

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

Non-small-cell Lung CancerMedicinePathologyFirst-line TreatmentCancer TreatmentCancer GeneticsOncologyRadiation OncologyLung CancerMolecular OncologyErlotinib Versus Chemotherapy